Transgene publishes investor presentation on individualized neoantigen cancer vaccines

Reuters2026/09/02 16:19

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Transgene published an investor presentation outlining its individualized neoantigen therapeutic vaccine platform, centered on MVA viral vectors.
Lead program TG4050 in resected head and neck cancer: Phase 1 showed 100% disease-free survival beyond three years; randomized Phase 2 ongoing.
Phase 2 readouts: preliminary immunogenicity in H2 2026; efficacy based on two-year disease-free survival by end of Q1 2028.
Second program TG4070 in resected non-small cell lung cancer: randomized Phase 1 ongoing with nivolumab; site initiation underway.
Presentation cites funding runway until early 2028; market cap about EUR 220 million; 160 employees in France.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transgene SA published the original content used to generate this news brief on September 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Transgene publishes investor presentation on individualized neoantigen cancer vaccines

You may also like

Crypto prices